Praxis Precision Medicines Praxis Precision Medicines (PRAX) - a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, announced the completion of a Type C meeting with the U.S. Food and Drug Administration (FDA) and agreement to immediately convert the EMBRAVE3 . . . This content is for paid subscribers. Please click here to …

Praxis Precision Medicines in the NEWS  On Aug. 04, 2025, the biopharmaceutical company Praxis Precision Medicines (PRAX), translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance provided a corporate update and reported financial results for the second quarter 2025. From Praxis Precision Medicines “In the second quarter, we continued to make remarkable progress across our portfolio …